Erin A. Kuang

Dr. Erin A. Kuang

Tulane University, New Orleans, Louisiana, USA
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 June 2022 in Pathogens
Verified
Journal Article
Open access
PDF file
EKErin A. Kuang
Erin A. Kuang
RCRobert W. Cross
Robert W. Cross
MMMaria McCavitt-Malvido
Maria McCavitt-Malvido
DADafna M. Abelson
Dafna M. Abelson
VBViktoriya Borisevich
Viktoriya Borisevich
ZBZachary Bornholdt
Zachary Bornholdt
Intravenous (IV) administration of antiviral monoclonal antibodies (mAbs) can be challenging, particularly during an ongoing epidemic, due to the considerable resources required for performing infusions. An ebolavirus therapeutic administered via intramuscular (IM) injection would reduce the burdens associated with IV infusion and allow rapid treatment of exposed individuals during an outbreak. Here, we demonstrate how MBP134, a cocktail of two pan-ebolavirus mAbs, reverses the course of Sudan ebolavirus disease (Gulu variant) with a single IV or IM dose in non-human primates (NHPs) as late as five days post-exposure. We also investigate the utility of adding half-life extension mutations to the MBP134 mAbs, ultimately creating a half-life extended cocktail designated MBP431. When delivered as a post-exposure prophylactic or therapeutic, a single IM dose of MBP431 offered complete or significant protection in NHPs challenged with Zaire ebolavirus. In conjunction with previous studies, these results support the use of MBP431 as a rapidly deployable IM medical countermeasure against every known species of ebolavirus.

2 January 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
KHKalen M. Hall
Kalen M. Hall
LWLeonard G. Williams
Leonard G. Williams
RSRichard D. Smith
Richard D. Smith
EKErin A. Kuang
Erin A. Kuang
RERobert Ernst
Robert Ernst
ZPZachary F. Pursell
Zachary F. Pursell
Bacteria of clinical importance, such as Pseudomonas aeruginosa, can become hypermutators upon loss of DNA mismatch repair (MMR) and are clinically correlated with high rates of multidrug resistance (MDR). Here, we demonstrate that hypermutated MMR-deficient P. aeruginosa has a unique mutational signature and rapidly acquires MDR upon repeated exposure to first-line or last-resort antibiotics. MDR acquisition was irrespective of drug class and instead arose through common resistance mechanisms shared between the initial and secondary drugs. Rational combinations of drugs having distinct resistance mechanisms prevented MDR acquisition in hypermutated MMR-deficient P. aeruginosa. Mutational signature analysis of P. aeruginosa across different human disease contexts identified appreciable quantities of MMR-deficient clinical isolates that were already MDR or prone to future MDR acquisition. Mutational signature analysis of patient samples is a promising diagnostic tool that may predict MDR and guide precision-based medical care.

4 August 2026 in Chemical Reviews
Verified
Journal Article
Open access
ATAdrian J. Taveras
Adrian J. Taveras
EKErin A. Kuang
Erin A. Kuang
RFRyan P. Ferrie
Ryan P. Ferrie
AEAce Ellis
Ace Ellis
ATAlaina Tait
Alaina Tait
WWWilliam Wimley
William Wimley
Lipid bilayer membranes are essential cellular permeability barriers that strictly limit the passage of polar molecules and macromolecules, thereby compartmentalizing cellular biochemistry and limiting the accessible chemical space for therapeutics. Membrane-traversing peptides (MTPs) are a diverse group of peptides defined by the ability to traverse synthetic or cellular membranes without causing permeabilization and without the assistance of specific transport proteins. These peptides fundamentally defy classical thermodynamic models of membrane permeability as they can cross lipid bilayers and deliver large polar cargoes, including peptides and proteins, into cells, despite having high net charge and low hydrophobicity. In this review, we challenge the idea of single, discrete mechanisms to describe how peptides traverse membranes and define a broad mechanistic landscape shaped by the conserved properties of MTPs and the unique physical chemistry and polymorphic phase behavior of lipid bilayers. We describe experimental assays and model systems that can be used to study MTP translocation and cargo delivery in synthetic systems and living cells. We use information obtained from comprehensive databases to consider the shared physical chemical space of MTPs. We also discuss key unanswered questions regarding mechanism, specificity, endosomal escape, and in vivo performance. Finally, we discuss illustrative examples and emerging translational applications of MTPs in intracellular drug delivery and molecular therapeutics. Together, these perspectives underscore the dual importance of MTPs as probes for fundamental biophysical studies of cell membranes and as promising tools to expand the universe of druggable intracellular targets.